A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.
about
Tamoxifen: catalyst for the change to targeted therapyFourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancerDevelopment of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancerThe discovery and development of selective estrogen receptor modulators (SERMs) for clinical practicePrediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical methodStructure-activity relationships of estrogensStructure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cellsTargeting the American market for medicines, ca. 1950s-1970s: ICI and Rhône-Poulenc comparedComparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond.Effects of tamoxifen on vaginal blood flow and epithelial morphology in the ratComparative temporal and dose-dependent morphological and transcriptional uterine effects elicited by tamoxifen and ethynylestradiol in immature, ovariectomized mice.Tamoxifen as the first targeted long-term adjuvant therapy for breast cancerTransient administration of estradiol-17 beta establishes an autoregulatory loop permanently inducing estrogen receptor mRNA.The Impact of CYP2D6 Genotyping on Tamoxifen TreatmentMolecular determinants of tissue selectivity in estrogen receptor modulators.Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifenPharmGKB summary: tamoxifen pathway, pharmacokineticsGenotype-guided tamoxifen therapy: time to pause for reflection?Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.Tamoxifen: a most unlikely pioneering medicine.Tamoxifen and CYP2D6: a contradiction of data.The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulatorsEndoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1).CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectivesSimulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifenProven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale.Pharmacogenetics and pharmacogenomics of anticancer agents.The Conformation of the Estrogen Receptor Directs Estrogen-Induced Apoptosis in Breast Cancer: A Hypothesis.Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversyClinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.The antitumour activity of tamoxifen and monohydroxytamoxifen: a comparative study in the rat [proceedings]Contrasting subcellular responses to monohydroxytamoxifen and oestradiol benzoate in the immature rat uterus [proceedings]
P2860
Q24652988-E6A9E30E-40DA-46C5-A664-638BDB7A9DA5Q24685693-CD976101-1CB2-4631-88EE-6BF309DE2106Q26825584-FB649D52-52E3-47F7-97ED-8D9EF1A4AF70Q26830744-C53FE749-C149-41CA-8AC1-A8F418336FE4Q27650591-F063D358-0A4D-4AB3-8938-4062349C2D8FQ28306714-2517587F-50BC-4DEC-9BF4-F0576AD8064EQ28343990-A06E957C-D3DC-49C8-A351-F6E35B467D6EQ28543555-1716A20C-09E5-46BA-959D-D29A9FBF9DADQ30416074-D8527615-4825-4B2D-B467-C0B99D848C48Q33257471-472040EC-7AF0-472C-B6ED-A2A0E3EC27D3Q33287050-6428004A-957E-443A-AE9C-F474A2A0F8EAQ33642104-EC770EBC-C14B-47FD-B666-91C106B633A5Q33650609-2527C45C-E06C-4E75-AC35-C701521407BEQ33664433-72B97B7E-4B13-4BE2-99BF-A31CCABD92ADQ33747238-C2A92B29-D0C1-4899-93A3-80732196F4F9Q33761834-1FAA67FD-3BA0-4E6D-A834-6A499F128433Q33841524-4A090061-AE60-487D-A3EE-07FE9B1E04F2Q33855494-D59165EA-B35C-4664-B6F5-1E13272964C6Q33955759-31A4671C-5CE3-48A9-B197-9A1602BC02F9Q34095909-D6FD277B-4D1F-4DAE-A834-D22267B22D75Q34180688-7BCCCE56-02CF-4357-9F63-C746E820AB54Q34244463-6CB3B10A-18A3-4D9E-A492-B141176EA690Q34311300-082612D0-0F05-4C9C-A0A4-87CE2C36FBA1Q34315816-D6CBC6D8-B60C-46E4-BFCF-C47ADF2425A3Q34360041-9BE48FD4-079F-401B-98D2-10EE7E5F4AFFQ34381754-8322B592-E2CC-446E-B42A-88945169068EQ34677193-CBADC7E7-E19D-4E99-A6A0-C7EA252D18B0Q34736075-0EC6D5E1-2863-43A3-85F7-B4DB023559D3Q34736986-1F01F55A-918D-4E77-9B2C-9C00D4B1D60CQ34774040-AB263CF6-7DC4-46BD-BA91-63809175D67CQ34774649-9A122EE4-54E1-4916-BBE9-B023A873A6F1Q34914140-95C7C8D7-BB6F-4D64-86A9-4D2C64ED5EF5Q35006860-E2709E05-A437-4542-98F6-CBFBE4632D61Q35023715-8D278E33-B4B5-41A5-A2FC-687FA8C58B40Q35030489-184C8BC7-264F-4309-916C-535FD9FF4CA8Q35030765-C7F69887-D406-4F14-A424-765910C95761Q35056229-FC7BCD81-E5A2-4F8A-BB84-F285584B8331Q35058455-B09333D7-8F40-4C96-8EC8-A7FA355FA9DDQ35177898-0FCB2B80-3821-4EAC-92A1-BA34B84C970CQ35177935-AF5C0FC7-8BE2-49DB-A9C5-CB2455380BED
P2860
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年学术文章
@wuu
1977年学术文章
@zh
1977年学术文章
@zh-cn
1977年学术文章
@zh-hans
1977年学术文章
@zh-my
1977年学术文章
@zh-sg
1977年學術文章
@yue
1977年學術文章
@zh-hant
name
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.
@en
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.
@nl
type
label
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.
@en
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.
@nl
prefLabel
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.
@en
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.
@nl
P2093
P356
P1476
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.
@en
P2093
P304
P356
10.1677/JOE.0.0750305
P407
P577
1977-11-01T00:00:00Z